Brokerages Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post -$0.55 EPS

Wall Street brokerages expect Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) to announce earnings per share of ($0.55) for the current quarter, according to Zacks. Zero analysts have made estimates for Rhythm Pharmaceuticals’ earnings. The business is expected to issue its next quarterly earnings results on Tuesday, February 13th.

On average, analysts expect that Rhythm Pharmaceuticals will report full-year earnings of ($1.64) per share for the current financial year, with EPS estimates ranging from ($1.73) to ($1.54). For the next year, analysts expect that the business will report earnings of ($2.05) per share, with EPS estimates ranging from ($2.37) to ($1.72). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that cover Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its quarterly earnings data on Tuesday, November 14th. The company reported ($1.78) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.40) by ($1.38).

RYTM has been the subject of a number of recent analyst reports. Morgan Stanley initiated coverage on Rhythm Pharmaceuticals in a research note on Monday, October 30th. They set an “equal weight” rating and a $23.00 price objective for the company. Cowen initiated coverage on Rhythm Pharmaceuticals in a research note on Monday, October 30th. They set an “outperform” rating and a $40.00 price objective for the company. BidaskClub upgraded Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, January 29th. Bank of America began coverage on Rhythm Pharmaceuticals in a research report on Monday, October 30th. They issued a “buy” rating and a $30.00 target price for the company. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $32.00 target price on shares of Rhythm Pharmaceuticals in a research report on Tuesday, November 14th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $31.25.

Shares of Rhythm Pharmaceuticals (NASDAQ:RYTM) opened at $25.14 on Wednesday. Rhythm Pharmaceuticals has a 12 month low of $21.38 and a 12 month high of $33.81. The firm has a market capitalization of $685.92 and a P/E ratio of -17.83.

Institutional investors and hedge funds have recently modified their holdings of the company. Wells Fargo & Company MN acquired a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth approximately $131,000. American International Group Inc. acquired a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth approximately $161,000. The Manufacturers Life Insurance Company acquired a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth approximately $184,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth approximately $309,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of Rhythm Pharmaceuticals in the 4th quarter worth approximately $523,000. Institutional investors own 10.05% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Brokerages Anticipate Rhythm Pharmaceuticals Inc (RYTM) to Post -$0.55 EPS” was originally posted by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/14/brokerages-anticipate-rhythm-pharmaceuticals-inc-rytm-to-post-0-55-eps.html.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. The Company’s lead peptide product candidate is setmelanotide, a potent, first-in-class melanocortin-4 receptor, or MC4R, agonist for the treatment of rare genetic disorders of obesity.

Get a free copy of the Zacks research report on Rhythm Pharmaceuticals (RYTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply